Testing a new drug for advanced head and neck cancer
Part of Cancer clinical trials.
This trial is testing an experimental drug called CD-001 for people with advanced head and neck cancer who have run out of standard treatment options. The goal is to see if the drug is safe and if it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced head and neck cancer that has not responded to or cannot tolerate standard treatments.
- You are able to do daily activities with some help (ECOG score of 0-2).
- You have at least one tumor that can be measured on a scan.
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a combination of two targeted drugs for advanced head and neck cancer that has not responded to standard treatments. It specifically includes patients whose tumors have a change in the CDKN2A gene.
This trial tests a new cancer medication for people with head and neck cancer that has come back or spread to other parts of the body. The study aims to see if this drug can help slow or shrink the cancer and improve survival.
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
This trial tests a new drug combination (BL-B01D1 plus a PD-1 inhibitor) for people with advanced head and neck cancer or other solid tumors that have come back or spread. It aims to see if the treatment can help shrink tumors or slow the disease.
Hear when a new Head &Amp; Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.